Last reviewed · How we verify

NCT06660927

The Study on the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System

Active, enrolled NA Last updated 28 October 2024
What this trial tests

NA trial testing liac Bifurcation Stent Graft System in Common Iliac Artery Aneurysm in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
30 November 2021
Primary endpoint
30 November 2025
30 November 2025

Quick facts

Lead sponsorLifetech Scientific (Shenzhen) Co., Ltd.
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment500
Start date30 November 2021
Primary completion30 November 2025
Estimated completion30 November 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Lifetech Scientific (Shenzhen) Co., Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with Common Iliac Artery Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Lifetech Scientific (Shenzhen) Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06660927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing